Crinetics Pharmaceuticals (CRNX) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CRNX Hot Sheet
Join SI Premium – FREE
Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($1.29), $0.05 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $4 million.
For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Sun Life Financial (SLF) Tops Q3 EPS by 2c
- Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 EPS by 12c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
